fig3
![Metabolic reprogramming as an emerging mechanism of resistance to endocrine therapies in prostate cancer](https://image.oaes.cc/eda39c04-dda5-4f38-bc6b-ddee20ec698c/3826.fig.3.jpg)
Figure 3. Metabolomics and metabolic imaging applications in PCa. Schematic overview of metabolomics and metabolic imaging applications in biomarker discovery and in therapy response assessment. ADT: androgen deprivation therapy; ARSI: androgen receptor signaling inhibitors; MSI: mass spectrometry imaging; MRI: magnetic resonance imaging; MRSI: magnetic resonance spectroscopy imaging; PET: positron emission tomography